Neuroendocrine tumors and survival rates in MEN-1 patients: impact of gender difference.

Among 100 MEN-1patients enrolled, 59 (59%) were female and 41 (41%) male, mean age at diagnosis was 39.4 years (range 5-86). No statistically significant association was identified between MEN-1 clinical manifestations and gender (primary hyperparathyroidism PHPT p: 1.0, DP-NET p: 0.83, pituitary adenoma PA p: 0.84, lung NET p: 0.64 and thymic NET p: 0.10), similarly age at diagnosis of MEN1 and its individual manifestations was similar between genders. Survival analysis revealed no statistically significant difference between genders in DP-NET patients regarding progression disease p:1.0 and death p:1.0. Mean progression free survival (PFS) of patients with DP-NET was 98.6 months (range 3-288), mean overall survival (OS) was 130.1 months (range 3-444 months), without differences between genders (PFS p: 0.67 and OS p: 0.60). The Kaplan-Meier survival curves for PFS and OS showed no differences between genders (PFS p: 0.92; OS p: 0.87).

Informations de copyright

S. Karger AG, Basel.